🔍

BALAXI - Balaxi Pharma

📊 NSE: BALAXI 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:58

📢 Recent Corporate Announcements

Balaxi Pharma Q3 FY26: Revenue at ₹72.54 Cr, PAT Declines to ₹0.31 Cr Amid Strategic Shift

🔵 WATCH ⭐ 7/10

EARNINGS 📅 29 Jan 2026, 02:45 PM

Balaxi Pharmaceuticals reported a marginal 1% YoY decline in Q3 FY26 revenue to ₹72.54 crore, though it saw a strong 29% sequential recovery from Q2. Profit After Tax (PAT) dropped significantly to ₹0.31 crore from ₹5.36 crore last year, primarily due to higher operating costs and challenges in the Angola market's institutional segment. The company successfully completed the qualification and validation of its first pharmaceutical formulation facility in Hyderabad, marking a shift to an 'Asset Right' model. Despite near-term margin pressure, the LATAM region remains a strong growth driver with 13 new product registrations added this quarter.

Revenue for Q3 FY26 stood at ₹72.54 crore, showing a 29% QoQ growth despite a 1% YoY dip.
PAT plummeted to ₹0.31 crore from ₹5.36 crore YoY due to elevated operating costs in institutional segments.
Total product registrations reached 948 across geographies, with 13 new registrations added in Q3.
The new Jadcherla formulation facility is now audit-ready, completing qualification and validation of equipment.
Gross margins moderated to 42% compared to 48% in the previous year's corresponding quarter.

💡 Investors should monitor the margin recovery as the new manufacturing facility begins to contribute to backward integration. The transition from 'Asset Light' to 'Asset Right' is a major strategic shift that may weigh on short-term profits but improve long-term supply chain control.

Balaxi Pharma Reports Zero Deviation in Utilization of ₹47.57 Crore Raised Funds

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 28 Jan 2026, 03:39 PM

Balaxi Pharmaceuticals has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that funds raised through its preferential issue are being used as intended. Out of the total ₹47.57 crore raised via equity shares and convertible warrants, the company has utilized approximately ₹34.22 crore to date. The proceeds are primarily being deployed for the construction of a new pharmaceutical formulation plant in Jadcherla, Hyderabad, and for working capital requirements. The report indicates zero deviation from the objects stated during the fundraise, reflecting disciplined financial management.

Total amount raised through preferential issue and warrant conversions is ₹47,56,92,250.
Cumulative funds utilized as of December 31, 2025, amount to ₹34,21,66,871.
The company reported zero deviation or variation in the use of proceeds for the reported quarter.
Funds are being utilized for capital expenditure on a new formulation plant in Jadcherla and general corporate purposes.

💡 Investors should view the lack of deviation as a positive sign of management integrity and focus on the upcoming Jadcherla plant as a key growth catalyst. Monitor the completion timeline of the facility to gauge future production capacity increases.

Balaxi Pharma Q3 Consolidated Net Profit Drops 94% YoY to ₹30.5 Lakhs; Jadcherla Plant Ready

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 02:55 PM

Balaxi Pharmaceuticals reported a significant decline in consolidated net profit to ₹30.50 lakhs for Q3 FY26, compared to ₹536.28 lakhs in the same period last year. While consolidated revenue remained relatively stable at ₹72.54 crore, higher administrative and employee expenses impacted the bottom line. On a positive note, the company's first pharmaceutical formulation plant at Jadcherla is now fully ready for CDSCO inspection following successful test manufacturing. Additionally, the Company Secretary and Compliance Officer has resigned effective January 29, 2026.

Consolidated Net Profit fell sharply to ₹30.50 lakhs in Q3 FY26 from ₹536.28 lakhs in Q3 FY25.
Consolidated Revenue from operations stood at ₹72.54 crore, a marginal decline from ₹73.29 crore YoY.
Jadcherla formulation facility is audit-ready for CDSCO inspection with successful test batches of Paracetamol and Piroxicam.
Consolidated EPS for the quarter dropped to ₹0.06 from ₹0.97 in the previous year's corresponding quarter.
Company Secretary Mohith Kumar Khandelwal resigned effective January 29, 2026.

💡 Investors should exercise caution as the sharp drop in profitability raises concerns despite stable revenues. The primary catalyst to watch is the successful CDSCO inspection and subsequent commercialization of the Jadcherla facility.

Balaxi Pharma Q3 Revenue Recovers to ₹72.5 Cr; Jadcherla Plant Ready for CDSCO Inspection

🔵 WATCH ⭐ 7/10

EARNINGS 📅 28 Jan 2026, 02:47 PM

Balaxi Pharmaceuticals reported a consolidated revenue of ₹72.54 crore for Q3 FY26, representing a strong 29% sequential growth compared to Q2 FY26, though it remained flat year-on-year. Consolidated net profit saw a sharp decline to ₹30.50 lakhs from ₹5.36 crore in the previous year's corresponding quarter, primarily due to increased administrative and employee costs. A major operational milestone was achieved as the Jadcherla formulation plant reached full readiness for CDSCO inspection after successful test manufacturing. The company also announced the resignation of its Company Secretary, Mohith Kumar Khandelwal, effective January 29, 2026.

Consolidated Revenue from operations for Q3 FY26 stood at ₹72.54 crore, up from ₹56.18 crore in Q2 FY26.
Consolidated Net Profit fell significantly to ₹30.50 lakhs from ₹5.36 crore in Q3 FY25.
Jadcherla formulation facility is 100% ready for CDSCO inspection with successful test batches of Paracetamol and Piroxicam completed.
Administrative expenses increased to ₹7.50 crore in Q3 FY26 compared to ₹6.15 crore in Q3 FY25.
Nine-month consolidated revenue for FY26 reached ₹199.46 crore with a net profit of ₹80.41 lakhs.

💡 Investors should focus on the upcoming CDSCO inspection results for the Jadcherla plant, as commercialization of this facility is the key catalyst for future margin improvement. While sequential revenue growth is positive, the sharp year-on-year profit compression warrants a cautious approach until operational leverage from the new plant kicks in.

Balaxi Pharmaceuticals Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 12:48 PM

Balaxi Pharmaceuticals has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, covers the period from October 1, 2025, to December 31, 2025. It confirms that the company has processed dematerialization requests and mutilated physical certificates within the mandated 15-day timeframe. This is a standard procedural filing required for all listed entities in India to ensure regulatory transparency.

Compliance certificate submitted for the quarter ended December 31, 2025.
Confirmation provided by Registrar and Share Transfer Agent, Aarthi Consultants Private Limited.
Dematerialization requests were processed and physical certificates cancelled within 15 days of receipt.
The name of the depository has been substituted as the registered owner in the company's records.

💡 No action is required as this is a routine administrative filing. Investors should continue to monitor the company's upcoming quarterly financial results for material performance updates.

Balaxi Pharmaceuticals Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Dec 2025, 02:40 PM

Balaxi Pharmaceuticals Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's Q3 and nine-month financial results for the period ending December 31, 2025. The window will remain closed until 48 hours after the un-audited financial results are declared to the public. The specific date for the Board of Directors meeting to approve these results will be announced at a later time.

Trading window closure effective from January 1, 2026, for all designated persons.
Closure is related to the upcoming Q3 and nine-month financial results ending December 31, 2025.
Trading restriction will lift 48 hours after the official declaration of financial results.
The board meeting date for result approval is yet to be finalized and communicated.

💡 This is a routine regulatory compliance filing and does not require any immediate action. Investors should monitor for the upcoming announcement of the board meeting date to assess the company's Q3 performance.

View All BALAXI Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue for Q2 FY26 was INR 56.17 Cr, representing a 27.4% YoY decline from INR 77.38 Cr. The pharmaceutical product mix is dominated by Tablets at 42%, followed by Capsules at 16%, Injectables at 15%, and Liquids at 11%. The group also generates revenue from construction materials and FMCG products in Angola, though specific segment growth percentages for these are not disclosed.

Geographic Revenue Split

As of Q2 FY26, Africa (primarily Angola) accounts for 63% of revenue, while Latin America (LATAM), including the Dominican Republic and Guatemala, contributes 37%.

Profitability Margins

Gross Margin improved to 48.3% in Q2 FY26, up 540 bps from 42.9% in Q2 FY25. However, PAT Margin collapsed to 0.4% in Q2 FY26 from 5.9% in Q2 FY25, a decline of 550 bps, driven by increased marketing spend and a shift toward institutional sales.

EBITDA Margin

EBITDA Margin for Q2 FY26 was 2.1%, a significant contraction of 1158 bps from 13.7% in Q2 FY25. EBITDA fell 88.9% YoY from INR 10.59 Cr to INR 1.17 Cr.

Capital Expenditure

The company has transitioned to an 'Asset Right' model by commissioning its first pharmaceutical formulation plant in Jadcherla, Hyderabad. Additionally, the board approved an equity infusion of up to USD 4 million (approx. INR 33.5 Cr) into its Dubai subsidiary, Balaxi Global FZCO, for operational expansion.

Credit Rating & Borrowing

CRISIL revised the outlook to 'Negative' from 'Stable' on November 13, 2025, while reaffirming the long-term rating at 'CRISIL BBB+'. The revision is due to profitability pressure and an elongated working capital cycle. Gearing was healthy at 0.25 times as of March 31, 2025.

⚙️ Operational Drivers

Raw Materials

The company primarily procures finished pharmaceutical formulations (white-labeled) for its distribution business. With the new Jadcherla plant, raw materials will include Active Pharmaceutical Ingredients (APIs) for tablets, capsules, and injectables, though specific chemical names and cost percentages are not disclosed.

Import Sources

Historically sourced from various third-party manufacturers; the new manufacturing unit is located in a Pharma SEZ in Jadcherla, Hyderabad, India.

Key Suppliers

Not specifically named in the documents, but the company utilizes a network of third-party manufacturers for its branded and generic products.

Capacity Expansion

The company recently completed and commissioned its first pharmaceutical manufacturing facility in Jadcherla, Hyderabad, to integrate manufacturing with its existing distribution network.

Raw Material Costs

Gross profit of INR 27.14 Cr on revenue of INR 56.17 Cr implies direct material/procurement costs are approximately 51.7% of revenue as of Q2 FY26.

Manufacturing Efficiency

The Jadcherla plant is expected to drive operational integration and margin improvement, though specific utilization rates for the new facility are not yet reported.

Logistics & Distribution

The company operates as a conglomerate spanning four continents with a focus on front-end distribution in specialized markets like Angola and LATAM.

📈 Strategic Growth

Expected Growth Rate

10%

Growth Strategy

Growth is targeted through the 'Asset Right' model, utilizing the new Jadcherla manufacturing facility to capture higher margins. The company is also expanding its footprint in LATAM (Honduras, El Salvador) and shifting its business mix toward institutional sales to increase volume, supported by a USD 4 million investment in its Dubai distribution hub.

Products & Services

Pharmaceutical formulations including Antibiotics (41% of therapeutic mix), Analgesics (15%), and other medicines in Tablet, Capsule, and Injectable forms. Also sells construction materials and FMCG products in specific markets.

Brand Portfolio

Balaxi

New Products/Services

Expansion of the product portfolio through the new Jadcherla plant, focusing on branded generics (40% of current mix) and pure generics (60%).

Market Expansion

Targeting deeper penetration in LATAM markets including the Dominican Republic, Guatemala, Honduras, and El Salvador.

Market Share & Ranking

Established market position in Angola, Dominican Republic, and Guatemala; specific percentage ranking not disclosed.

Strategic Alliances

The group operates through various wholly-owned subsidiaries like Balaxi Global FZCO (Dubai) and local entities in Guatemala, Dominica, Honduras, and Central Africa.

🌍 External Factors

Industry Trends

The industry is seeing a shift toward local manufacturing and institutional procurement. Balaxi is positioning itself by moving from a pure distribution model to an integrated manufacturing-and-distribution ('Asset Right') model.

Competitive Landscape

Competes with other generic pharmaceutical exporters and local distributors in specialized emerging markets.

Competitive Moat

Moat is built on deep distribution expertise in difficult-to-penetrate markets and a 12-24 month regulatory lead time for product registrations, which creates a barrier to entry for competitors.

Macro Economic Sensitivity

Highly sensitive to the economic stability of Angola and Latin American countries. GDP fluctuations in these regions directly impact healthcare spending and construction demand.

Consumer Behavior

Demand is driven by essential healthcare needs (Antibiotics/Analgesics) and infrastructure development (construction materials) in emerging economies.

Geopolitical Risks

Vulnerable to economic uncertainties and regulatory changes in African and LATAM regions.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent local pharmaceutical registration processes (12-24 months) and compliance with local regulatory frameworks in each country of operation.

Taxation Policy Impact

The new manufacturing unit is located in a Pharma SEZ, which typically offers fiscal benefits; consolidated tax provision was INR 1.93 Cr for the reported period in the MDA.

Legal Contingencies

The company reported compliance with the Sexual Harassment of Women at Workplace Act with zero complaints received during the year. No major pending court cases with values were disclosed in the provided excerpts.

⚠️ Risk Analysis

Key Uncertainties

Currency volatility in Angola and the success of the transition to institutional sales are the primary uncertainties, with potential to impact net cash accruals if they fall below INR 20 Cr.